
In a breakthrough from the CASTLE HTx trial, patients battling symptomatic atrial fibrillation (AF) and end-stage heart failure (HF) have seen improved outcomes through a combination of catheter ablation and guideline-directed medical therapy, compared to medical therapy alone. This discovery underscores the significance of arrhythmia burden as a pivotal prognostic marker for individuals dealing with both AF and HF. The study offers new hope for enhanced treatment strategies in this patient group.
Like
Save
Share